Dinesh Patel, Protagonist Therapeutics CEO

De­spite mid-stage plaque pso­ri­a­sis win, J&J ap­pears un­de­cid­ed on PhI­II for part­ner's IL-23 drug

J&J and biotech part­ner Pro­tag­o­nist Ther­a­peu­tics claimed a Phase IIb win in plaque pso­ri­a­sis Tues­day morn­ing. But near-term plans for the drug re­main murky.

The study, look­ing at an oral IL-23 drug called JNJ-2113, hit its pri­ma­ry end­point in adults with mod­er­ate-to-se­vere plaque pso­ri­a­sis, the com­pa­nies said. Re­searchers saw more pa­tients who took the drug achieve PASI-75, or at least 75% im­prove­ment in skin le­sions, by a sta­tis­ti­cal­ly sig­nif­i­cant mar­gin com­pared to place­bo in all five treat­ment co­horts.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA